The S&P 500 Health Care sector ($SRHC) has been one of the weakest spots in the market in 2026, and Abbott Laboratories (ABT) has taken an even harder hit. As of May 4, 2026, Abbott shares closed at a new 52-week low of $87.54, down roughly 37.1% from the 52-week high of $139.06 set in June 2025. In just the last three months, ABT has dropped 19.85%.
That slide looks especially striking for a company generating $44.3 billion in annual revenue and reporting Q1 2026 sales of $11.16 billion, up 7.8% from a year earlier. Abbott also holds the rare status of being both a Dividend Aristocrat and a Dividend King, meaning it has raised its dividend for at least 50 straight years. Abbott’s most recent quarterly payout was $0.63 per share, which works out to a 2.73% yield, more than double the S&P 500’s ($SPX) 1.1% average.
